Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EW
BUYEdwards Lifesciences Corporation · Healthcare · United States · $47.6B · Avg Vol: $433M/d
COMPANY DESCRIPTION
Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. The company's competitive moat is its proprietary technologies in heart valves and hemodynamic monitoring, strong intellectual property, and extensive clinical evidence supporting its innovative products. Edwards Lifesciences is a market leader in transcatheter aortic valve replacement (TAVR) and advanced hemodynamic monitoring, benefiting from a highly specialized and growing medical device market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.5B | 5.0B | 5.4B | 6.1B | 10.8% | 6.3B | 6.8B | 7.4B | 10.6% |
| EPS | 2.46 | 2.31 | 6.98 | 1.84 | -9.2% | 1.84 | 2.16 | 2.42 | 14.8% |
| Shares | 608.3M | 601.1M | 588.6M | 580.7M | -4.5% | 575.8M | — | — | — |
| Debt | 691.3M | 685.1M | 700.0M | 705.4M | 0.7% | 702.9M | — | — | — |
| Equity | 5.8B | 6.7B | 10.0B | 10.3B | 21.2% | — | — | — | — |
| Op CF | 1.2B | 895.8M | 542.3M | 1.6B | 9.4% | 1.4B | — | — | — |
| Inv CF | 252.3M | 173.8M | 2.3B | -712.9M | — | — | — | — | — |
| Fin CF | -1.6B | -711.0M | -983.0M | -956.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EW are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EW | Edwards Lifesciences Corporation(you) | $47.6B | 72 | BUY |
| BSX.MX | Boston Scientific Corporation | $66.0B | 63 | HOLD |
| GEHC.MX | GE HealthCare Technologies Inc. | $27.5B | 67 | BUY |
| DXCM | DexCom, Inc. | $27.6B | 83 | STRONG BUY |
| STE | STERIS plc | $20.9B | 81 | STRONG BUY |
| SYK | Stryker Corporation | $126.6B | 67 | BUY |
| ABL.DE | Abbott Laboratories | $164.9B | 70 | BUY |
| BIO-B | Bio-Rad Laboratories, Inc. | $8.3B | 72 | BUY |
| ZBH | Zimmer Biomet Holdings, Inc. | $17.7B | 91 | STRONG BUY |
| PEN | Penumbra, Inc. | $12.5B | 53 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%